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ABSTRACT
The immune receptor Tim-3 is often highly expressed in human acute myeloid leukemia (AML) cells
where it acts as a growth factor and inﬂammatory receptor. Recently, it has been demonstrated that
Tim-3 forms an autocrine loop with its natural ligand galectin-9 in human AML cells. However, the
pathophysiological functions of Tim-3 in human AML cells remain unclear. Here, we report for the ﬁrst
time that Tim-3 is required for galectin-9 secretion in human AML cells. However, this effect is
cell-type speciﬁc and was found so far to be applicable only to myeloid (and not, for example,
lymphoid) leukemia cells. We concluded that AML cells might use Tim-3 as a trafﬁcker for the
secretion of galectin-9 which can then be possibly used to impair the anticancer activities of cytotoxic





The T cell immunoglobulin and mucin domain 3 (Tim-3) is a
plasma membrane-associated protein which is highly
expressed in acute myeloid leukemia (AML) cells and is there-
fore considered as a potential target for anti-AML therapy.1,2
Although the biochemical activities of Tim-3 have recently
been elucidated,3-7 the functional role of this protein/receptor
in AML cells remains unclear and the reasons for striking
increases in Tim-3 levels in these cells are also not yet under-
stood. Galectin-9, which was found to be a natural Tim-3
ligand,3,5 was recently suggested to form an autocrine loop,
where newly released galectin-9 interacts with Tim-3
expressed on the cell surface.3 Furthermore, in leukocytes
Tim-3 is known to be shed by proteolytic enzymes including
metalloproteinases.8 This leads to the dissociation of Tim-3
from the plasma membrane as a soluble protein, which then
can be detectable in human blood plasma.8,9 The physiological
role of this shedding remains unclear as well as the functions
of soluble Tim-3. However, it is known that galectin-9 is capa-
ble of impairing the immunological activities of cytotoxic T
cells as well as natural killer (NK) cells1,10,11 In cytotoxic T
cells galectin-9 was found to induce apoptotic death,11 while
in NK cells it mainly affected cytokine production thus
impairing their cytotoxicity function.10 These effects might
therefore help AML cells to escape immune attack by both
cytotoxic T cells and NK cells.1,10,11
Given the above, we hypothesized that Tim-3 might act as a
trafﬁcker for galectin-9 in AML cells. We found that galectin-9
is expressed in the AML cell line THP-1, in primary human
AML cells, and in primary healthy human leukocytes (although
in this case the expression was considerably lower). Galectin-9
is capable of forming a stable complex with Tim-3 in cell
lysates. We also detected that in THP-1 and U-937 cell lines as
well as in primary healthy leukocytes the surface presence of
Tim-3 is much lower compared to primary human AML cells.
The same effect was observed for galectin-9. Galectin-9 knock-
down in U-937 cells reduced their total Tim-3 levels. Further-
more, Tim-3 knockdown in U-937 cells did not show
reductions in intracellular galectin-9 levels but galectin-9 secre-
tion was dramatically reduced. We therefore suggested that
Tim-3 is required for galectin-9 secretion in AML cells. Pri-
mary human chronic lymphoid leukemia (CLL) cells were also
capable of secreting galectin-9 but expressed very low amounts
of Tim-3. These results suggest that Tim-3 might be required
for galectin-9 secretion in AML cells. Using ELISA, we were
able to detect galectin-9 and soluble Tim-3 in human blood
plasma obtained from healthy donors. Furthermore, capturing
soluble Tim-3 on ELISA plates also led to detection of galectin-
9. These results suggest the presence of Tim-3-galectin-9 com-
plexes in human blood plasma but do not indicate whether
they are formed inside secreting cells, on their surface, or con-
stitutively present in blood plasma.
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Results
Galectin-9 is expressed in healthy primary human
leukocytes and malignant human myeloid cells and forms
a complex with Tim-3 in both cell types
We ﬁrst assessed whether healthy primary human leukocytes
(PHL) and malignant human myeloid cell lines express galec-
tin-9 and if its expression could be affected by pro-inﬂamma-
tory stimulation as well as growth factor-induced biological
responses. For this purpose, we used PHL which were isolated
from buffy coat blood obtained from healthy donors and
THP-1 human myeloid leukemia cells which were reported to
express galectin-9.6
We found that THP-1 cells produced more galectin-9 com-
pared to PHL, however, lipopolysaccharide (LPS, ligand of pro-
inﬂammatory Toll-like receptor (TLR) 412) and stem cell
growth factor (SCF—a major haematopoietic cytokine respon-
sible for the promotion of leukemia progression13) signiﬁcantly
upregulated galectin-9 levels in PHL (LPS was however shown,
to be a stronger activator). Interestingly, galectin-9 bands in
PHL cells appeared slightly lower on the gel compared to THP-
1 cells and the positive control (Fig. 1), suggesting potential dif-
ferences in post-translational processing. Only SCF was able to
signiﬁcantly increase galectin-9 levels in THP-1 cells (Fig. 1).
We then asked whether galectin-9 is capable of forming a
complex with Tim-3 in cell lysates. For this purpose, we coated
MaxiSorp ELISA plates with rabbit capture antibody directed
against galectin-9 followed by the addition of cell lysates (see
Materials and Methods). After incubation, galectin-9 was
extracted and detected by Western blot analysis using anti-
galectin-9 rabbit antibody. Tim-3 was also detected using
highly speciﬁc mouse antibody. We found that in both THP-1
and PHL cells Tim-3 and galectin-9 gave positive staining at
above 70 KDa which corresponds to the sum of Tim-3 and
galectin-9 molecular weights detected in these cells by Western
blot analysis (Fig. 2). Traces of free galectin-9 were still detect-
able, while Tim-3 was almost undetectable. The fact that SDS-
PAGE electrophoresis did not separate these proteins indicates
the formation of a stable complex. Since this did not occur with
recombinant proteins expressed in E. Coli (which lack glycosyl-
ation), it is reasonable to surmise that the lectin (galectin-9)
binds to sugar moieties on Tim-3 protein. The fact that both
un-complexed proteins were detected by Western blot in fresh
cell lysates suggests the requirement of both time and the pres-
ence of a surface (a solid phase—ELISA plate bottom in our
case) to form such a steady complex.
Next, we analyzed the cellular distribution of Tim-3 and
galectin-9 comparing intracellular levels with cell-surface
expressions. We used THP-1 and U-937 human myeloid cell
lines, primary human AML cells (AML-PB001F) as well as
PHL. We measured the total amounts of both proteins using
in-cell Western assay in comparison to the amounts present on
the cell surface using in-cell assay (also called on-cell assay; as
described in the Materials and Methods). We observed that
resting THP-1, U-937, and PHL cells expressed substantially
more Tim-3 and galectin-9 intracellularly than on the surface.
In contrast, primary AML cells had comparatively greater sur-
face presence of both proteins (Fig. 3). Interestingly the ratios
of Tim-3surface/Tim-3total and galectin-9surface/galectin-9total
were quite similar to each other in all studied cell types (Fig. 3).
Tim-3 is required for galectin-9 release in human myeloid
leukemia cells
We next asked whether Tim-3 is required for galectin-9
release and used U-937 cells (higher siRNA transfection efﬁ-
ciency could be reached with this cell line using our DOTAP
transfection method) to investigate our hypothesis. We also
studied if galectin-9 is required for Tim-3 production. First,
we knocked down galectin-9 expression in U-937 cells as
outlined in Materials and Methods. Non-treated normal and
galectin-9 knockdown U-937 cells as well as those treated
for 4 h with 2 mg/mL anti-Tim-3 stimulatory antibody5
were analyzed. Successful knockdown of galectin-9 was con-
ﬁrmed by Western blot analysis (Fig. 4A) as well as quanti-
tative real-time reverse transcription PCR (qRT-PCR;
Fig. S1). We found that galectin-9 knockdown reduced cellu-
lar Tim-3 levels as well as affecting galectin-9 levels (both
intracellular and released (Fig. 4A)). Previously, we reported
that Tim-3 activates the mTOR pathway resulting in upregu-
lation of glycolysis and release of pro-angiogenic vascular
endothelial growth factor (VEGF). We found that galectin-9
knockdown upregulated stimulatory phosphorylation of
mTOR (position S2448, Fig. 4B). This result was in line with
the upregulation of glycolysis and VEGF release (Fig. 4B).
Interestingly, we could not observe a signiﬁcant increase in
intracellular levels of methylglyoxal (MGO, Fig. 4B) in either
case, indicating that the efﬁciency of glycolysis correlates
with the activity of glycolytic enzymes, since MGO is
spontaneously formed out of dihydroxyacetone phosphate
when glycolytic enzymes are oversaturated. MGO catalyzes
Figure 1. Effects of LPS and SCF on galectin-9 protein expression in THP-1 cells
and PHL (abbreviated as PL in the ﬁgure). Cells were treated for 4 h with the indi-
cated concentrations of LPS and SCF, then harvested and galectin-9 protein
expression levels were analyzed by Western blot as outlined in Materials and Meth-
ods. Images are from one experiment representatives of three which gave similar
results. Human recombinant galectin-9 (R&D Systems) was used as a positive con-
trol. Data are mean values § SEM of three independent experiments; p < 0.05;
p < 0.01 vs. control.
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glycation followed by generation of advanced glycation end
products (Fig. S2). Higher amounts of these products could
be produced by cancer cells given their dependence on
glycolysis.
In Tim-3 knockdown U-937 cells (successful knockdown
was conﬁrmed by Western blot, Fig. 5A, and qRT-PCR,
Fig. S1), we saw a signiﬁcant reduction in Tim-3 levels. No
reduction in Tim-3/galectin-9 levels and no other effects were
observed when using negative control random siRNA (Fig. 5,
Fig. S1) which conﬁrmed the speciﬁcity of the events observed.
Tim-3 knockdown did not lead to changes in intracellular
galectin-9 levels but dramatically reduced galectin-9 secretion,
suggesting that Tim-3 is required for the release of galectin-9
(Fig. 5A). Reduction in Tim-3-mediated mTOR
phosphorylation at S2448 and respectively downregulation of
glycolysis/VEGF release was also observed in Tim-3 knock-
down U-937 cells. No signiﬁcant changes in MGO levels were
observed suggesting that glycolytic efﬁciency—a key energy
pathway in leukemia cells—was not affected (Fig. 5B).
Tim-3 is a speciﬁc trafﬁcker for galectin-9 in certain
cell types
It is generally known that many cell types, including lymphoid
cells, are capable of producing galectin-9 but not all of them
express Tim-3. We therefore compared the capability of pri-
mary human AML cells and primary human CLL cells to pro-
duce galectin-9. Both cell types secreted detectable amounts of
Figure 2. Galectin-9 and Tim-3 form a stable complex. Lysates obtained from 300,000 THP-1 cells or 1,500,000 PHL (abbreviated as PL in the ﬁgure; expression levels of
both proteins were ca. 5 times lower in PHL compared to THP-1) were loaded onto an ELISA plate pre-coated with rabbit anti-galectin-9 antibody as described in Materials
and Methods). Following incubation, captured proteins were extracted and subjected to Western blot analysis (see Materials and Methods for details). Both Tim-3 (using
mouse anti-Tim-3 antibody) and galectin-9 (using rabbit anti-galectin-9 antibody) were stained. Images are from one experiment representative of four which gave similar
results.
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galectin-9. In AML cells, but not in CLL cells, the amount of
secreted galectin-9 was signiﬁcantly increased by 4 h of expo-
sure to 2 mg/mL anti-Tim-3 (Fig. 6A). Both PHL and AML cells
expressed Tim-3 but this expression was much higher in AML
cells compared to PHLs (Tim-3/actin ratios were analyzed,
Fig. 6B). CLL cells expressed almost undetectable amounts of
Tim-3 but still they were capable of releasing galectin-9, indi-
cating that they probably use a different trafﬁcker for this
protein.
Finally, we observed that blood plasma of healthy donors
contained both galectin-9 and soluble Tim-3 as measured by
ELISA. Intriguingly, when capturing Tim-3 on the ELISA plate
and applying detection antibody directed against galectin-9 we
were able to detect a clear signal (Fig. 6C) which was not appli-
cable when intact cell culture medium or galectin-9 standards
were used. This means that a complex formed by non-cell-asso-
ciated soluble Tim-3 and galectin-9 is present in the blood
plasma of healthy donors. Our previous experiments demon-
strated that anti-Tim-3 antibody does not compete with
galectin-9.5
Discussion
Galectin-9 is a typical galectin family member which has a
tandem structure.10,14 It has been reported to speciﬁcally
interact with the immune receptor Tim-3 inducing mTOR
pathway activation as well as forming an autocrine loop
with Tim-3 in human AML cells.3,5 Due to very high
expression levels of Tim-3 in AML cells this protein is cur-
rently considered as a target for anti-AML therapy. Further-
more, galectin-9 was reported to speciﬁcally target cytotoxic
T cells and NK cells and impair their ability to attack and
kill leukemia cells.10,11,15
Our present study clearly shows that human myeloid leuke-
mia cells express and secret galectin-9 (Figs. 1, 3, and 7 and
Fig. S1). Importantly, galectin-9 production is upregulated by
pro-inﬂammatory stimulation (LPS) and growth factor (SCF)
action in both healthy human leukocytes and AML cells (THP-
1 cell line). Release of galectin-9 was clearly dependent on the
Tim-3. Tim-3 knockdown in U-937 cells led to signiﬁcant
reductions in galectin-9 secretion compared to normal (wild
type) U-937 cells (Fig. 5A). Tim-3 protein levels were also
reduced (but not signiﬁcantly) in galectin-9 knockdown U-937
cells compared to wild type cells (Fig. 4A). However, Tim-3
mRNA levels were signiﬁcantly downregulated in galectin-9
knockdown U-937 cells ( Fig. S1) suggesting that transcription
of the Tim-3 gene depends on intracellular levels of galectin-9.
Interestingly, Tim-3 knockdown did not affect intracellular
galectin-9 levels in U-937 cells, as measured by Western blot
analysis, but dramatically reduced the capability of these cells
to secrete galectin-9. These results suggest that galectin-9 levels
inﬂuence Tim-3 expression at a genomic level, whereas Tim-3
Figure 3. Comparative analysis of total and surface-based Tim-3 and galectin-9 proteins in human myeloid leukemia cell lines, PHL, and primary human AML cells. The
indicated numbers of resting U-937 and THP-1 cells, PHL and primary human AML cells (AML-PB001F) were subjected to in-cell assay (ICA, detecting surface proteins) or
in-cell Western (ICW, total protein detection) analysis as described in Materials and Methods. Images are from one experiment representative of ﬁve which gave similar
results. Data are mean values § SEM of ﬁve independent experiments; p < 0.05; p < 0.01 vs. control.
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protein controls the capability of myeloid leukemia cells to
secrete galectin-9.
Recent evidence demonstrated that A disintegrin andmetal-
loproteases (ADAM) 10 and 17 control shedding of Tim-3
from the cell surface in HEK-293 cells and human primary
CD14C monocytes.8 This suggests that Tim-3 might undergo
shedding when it is in complex with galectin-9, which allows
dissociation of the Tim-3 fragment together with the full-length
galectin-9 protein. This hypothesis might explain why LPS
reduces cellular Tim-3 surface expression6,8 taking into account
our results demonstrating LPS-induced upregulation of galec-
tin-9 levels. Our previous study demonstrated that Tim-3 pro-
tein production is not reduced by LPS5 while surface presence
is affected.6,8 This might be the result of increased intracellular
galectin-9 levels leading to enhanced galectin-9 secretion
which, as we have described above, requires Tim-3. ADAM10/
17 or other proteolytic enzymes can then possibly shed the
Tim-3/galectin-9 complex. Further evidence also supports the
rapid shedding process such as via ligand-induced Tim-3-
mediated activation of the mTOR pathway.
Although Tim-3 is a weaker signal transducer compared to
Kit (SCF receptor) or TLR4, a moderate level of mTOR activa-
tion could be the result of swift removal of the extracellular
domain which terminates the signal prematurely compared to
those observed for non-cleaved receptors (as TLR4 or Kit).
Furthermore, in support of a Tim-3/galectin-9 complex shed-
ding scenario, other factors, such as HIV-1 infection, lead to
increases in both soluble Tim-3 and galectin-9 levels in blood
plasma.9,16 Also, phorbol 12-myriastate 13-acetate (PMA) was
found to upregulate galectin release in Jurkat T cells,17 where
Figure 4. The effects of galectin-9 knockdown on Tim-3 expression and the mTOR pathway. Non-treated normal (wild type) and galectin-9 knockdown U-937 cells, as well
as those which underwent 4 h treatment with 2 mg/mL anti-Tim-3 stimulatory antibodies, were analyzed for Tim-3 and galectin-9 levels, galectin-9 release (A), pS2448
mTOR intracellular levels, glycolysis, MGO, and VEGF secretion (B). Images are from one experiment representative of three which gave similar results. Data are mean
values § SEM of 3–5 independent experiments; p < 0.05; p < 0.01 vs. control; a p< 0.05; aap < 0.01 vs. anti-Tim-3.
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it also upregulates Tim-3 expression/externalisation.18 PMA is
also known to promote Tim-3 proteolytic shedding.8 Matrix
metalloproteinase inhibitor BB-94 (ADAM10 was also found
to be sensitive to it19) was able to abolish PMA-induced
galectin-9 release in Jurkat T cells (immortalised T lympho-
cytic cell line derived from T cell leukemia17), suggesting that
proteolysis is probably involved in shedding Tim-3 complexed
with galectin-9.
Our results also demonstrated that CLL bone marrow
mononuclear cells (containing elevated levels of CD4C T cells
with a cytotoxic phenotype20) are capable of secreting galectin-
9 but they only produce very low amounts of Tim-3 (Figs. 6A
and B ). This suggests that Tim-3 is a cell type-speciﬁc trafﬁcker
of galectin-9 in AML cells, while other cell types (such as CLL
bone marrow mononuclear cells) might use other galectin-9-
speciﬁc proteins, which can be externalized. In support of this,
Figure 5. Tim-3 is required for galectin-9 secretion in human myeloid leukemia cells. Non-treated normal (wild type), Tim-3 knockdown and transfected with random
siRNA U-937 cells, as well as the same cells which underwent 4 h treatment with 2 mg/mL anti-Tim-3, were subjected to analysis for Tim-3 and galectin-9 levels, galectin-
9 release (A), pS2448 mTOR intracellular levels, glycolysis, MGO, and VEGF secretion (B). Images are from one experiment representative of three which gave similar
results. Data are mean values § SEM of 3–5 independent experiments; p < 0.05; p < 0.01 vs. control; ap < 0.05; aap < 0.01 vs. anti-Tim-3; bp < 0.05; bbp < 0.01 vs.
random siRNA.
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there is evidence that galectin-9 may cause Tim-3-independent
effects (including apoptosis) in lymphoid cells.10,21
In human blood plasma obtained from healthy donors, we
found that both galectin-9 and soluble Tim-3 are present
(Fig. 6C). However, anti-Tim-3 detection antibodies also gave
rise to a positive signal to visualize the product captured by
anti-galectin-9 antibody (Fig. 6C). This clearly indicates that a
Tim-3/galectin-9 complex is present in human blood plasma.
However, our results do not provide any indication at which
point the complex was formed.
Figure 6. Galectin-9 and Tim-3 levels in primary human AML, CLL, and PHL cells as well as in blood plasma. (A) Non treated primary human AML and CLL cells, as well as
those exposed for 4 h to anti-Tim-3, were precipitated and medium was subjected to measurement of galectin-9 by ELISA. Data represent mean values § SEM of three
independent experiments; p < 0.05 vs. control. (B) PHL, primary human AML, and CLL cells were subjected to Western blot analysis for Tim-3. Images are from one
experiment representative of four which gave similar results. Data are mean values § SEM of four independent experiments. (C) Blood plasma of six healthy donors was
subjected to ELISA assays for galectin-9, soluble Tim-3, and Tim-3-galectin-9 complex (for details, please see Materials and Methods and diagrams underneath the table).
Data are mean values § SEM of 3–5 independent experiments.
Figure 7. Tim-3-dependent secretion of galectin-9 in human AML cells could potentially impair the anti-leukemic activity of cytotoxic T cells and NK cells.
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Our results suggest that Tim-3 is required for galectin-9
secretion in AML cells and this mechanism may be then
used to impair the anticancer activity of cytotoxic T cells
and NK cells, which might allow malignant blood cells to
escape immune attack. Our hypothesis is summarized in
the Fig. 7.
Our ﬁndings also demonstrated that decrease in intracellular
galectin-9 level increases mTOR activity and its downstream
effects (efﬁcient glycolysis and VEGF production, Fig. 4A). In
myeloid leukemia cell lines as well as in PHL, the activity of the
mTOR pathway is always lower than in primary AML cells.4,5
One of the reasons for this might be externalisation of the Tim-
3/galectin-9 complex in primary AML cells (conﬁrmed in our
studies—see Fig. 3). In this case, while there are lower amounts
of galectin-9 inside the cells Tim-3/galectin-9 complexes are
externalized on the cell surface, which can initiate signaling
events before further modiﬁcation or proteolytic shedding.
These effects are presented in Fig. 8, which summarizes Tim-3
signal transducing activities in PHL/AML cell lines compared
with primary human AML cells.
Our results also highlight that both Tim-3 and galectin-9 are
promising therapeutic targets for possibly curing AML.
Absence of the Tim-3/galectin-9 autocrine loop or the timely
capture and subsequent inactivation of biologically active galec-
tin-9 may reduce the ability of AML cells to impair the antican-
cer activities of NK cells and cytotoxic T cells. This may
therefore result in the natural eradication of cancer cells by
functional NK cells and cytotoxic T cells.
Figure 8. Distribution of complexes and corresponding effects of Tim-3 and galectin-9 in healthy and malignant human white blood cells. (A) Scheme demonstrating
intracellular signaling pathways induced by Tim-3-galectin-9 complexes. (B) Tim-3/galectin-9 distribution and corresponding effects in PHL and human myeloid leukemia
cell lines (THP-1 and U-937). (C) Tim-3/galectin-9 distribution and corresponding effects in primary human AML cells.
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Materials and methods
Materials
RPMI-1640 medium, foetal bovine serum and supplements,
LPS (from P. aeruginosa), DOTAP transfection reagent, pri-
mers and galectin-9 silencing RNA (siRNA) were purchased
from Sigma (Suffolk, UK). MaxisorpTM microtitre plates
were provided either by Nunc (Roskilde, Denmark) or were
a kind gift of Oxley Hughes Ltd (London, UK). Mouse
monoclonal antibodies directed against mTOR and b-actin
as well as rabbit polyclonal antibodies against phospho-
S2448 mTOR, galectin-9, Tim-3, and HRP-labeled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Goat anti-mouse and goat anti-rabbit
ﬂuorescence dye-labeled antibodies were obtained from
Li-Cor (Lincoln, Nebraska USA). ELISA-based assay kits for
the detection of VEGF were purchased from Bio-Techne
(R&D Systems, Abingdon, UK). All other chemicals pur-
chased were of the highest grade of purity.
Primary human AML and CLL cells
Primary human AML mononuclear blasts (AML-PB001F,
newly diagnosed/untreated) were purchased from AllCells
(Alameda, CA, USA) and handled in accordance with manu-
facturer’s instructions. Primary human bone marrow derived
CLL mononuclear cells (CLL-BM001F, newly diagnosed/
untreated leukemia) were also obtained from AllCells
(Alameda, CA, USA) and handled in accordance with manu-
facturer’s protocol. Cells from six different patients were ana-
lyzed following ethical approval (REC reference: 16-SS-033).
THP-1 and U937 human myeloid cell lines
THP-1 human myeloid leukemia monocytes and U937
human myeloid monocytes were obtained from the
European Collection of Cell Cultures (Salisbury, UK). Cells
were cultured in RPMI 1640 media supplemented with 10%
foetal bovine serum, penicillin (50 IU/mL) and streptomycin
sulfate (50 mg/mL).
Primary human leukocytes obtained from healthy donors
(buffy coats)
PHL were obtained from buffy coat blood (originated from
healthy donors undergoing routine blood donation) which
was purchased from the National Health Blood and Trans-
fusion Service (NHSBT, UK) following ethical approval
(REC reference: 16-SS-033). Mononuclear-rich leukocytes
were obtained by Ficoll-density centrifugation according to
the manufacturer’s protocol. Cell numbers were counted
using a haemocytometer and diluted accordingly with
HEPES-buffered Tyrode’s solution before the indicated
treatments.4
Stem cell factor
Human SCF protein was produced in E. Coli and puriﬁed in
accordance with previously published protocols.20
Transfer of Galectin-9/Tim-3 siRNA into U-937 cells and
qRT-PCR
We employed a galectin-9-speciﬁc siRNA target sequence (uga
ggu gga agg cga ugu ggu ucc c) which was previously
described.14 For Tim-3 knockdown, we used commercially
available siRNA purchased from Santa Cruz Biotechnology,
CA, USA, as described before.7 As a control, we used corre-
sponding random siRNA (uac acc guu agc aga cac c dtdt22).
Transfection into U-937 cells was performed using DOTAP
reagent according to the manufacturer’s protocol.
To monitor galectin-9 and Tim-3 mRNA levels, we used
qRT-PCR.21 Total RNA was isolated using a GenEluteTM mam-
malian total RNA preparation kit, followed by a target protein
mRNA reverse transcriptase–polymerase chain reaction
(RT-PCR) performed in accordance with the manufacturer’s
protocol (Sigma). This was followed by quantitative real-time
PCR. Primer selection was as follows: Galectin-9, 50-CTTTCAT-
CACCACCATTCTG-30, 50-ATGTGGAACCTCTGAGCACTG-
30 Tim-3, 50-CATGTTTTCACATCTTCCC-30 actin, 50-TGACG
GGGTCACCCACACTGTGCCCATCTA-30, 50-CTAGAAGC
ATTTGCGGTCG-ACGATGGAGGG-30. Reactions were per-
formed using a LightCycler 480 real-time PCR system and
respective SYBR Green I Master kit (obtained from Roche, Burgess
Hill, UK). Analysis was performed according to the manufacturer’s
protocol. Values representing galectin-9 and Tim-3 mRNA levels
were normalized against b-actin.
Western blot analysis
Expressions of Tim-3 and galectin-9 were determined by
Western blot analysis and compared to b-actin in order to
determine equal protein loading, as previously described.4 Li-
Cor goat secondary antibodies, conjugated with ﬂuorescent
dyes, were used in accordance with manufacturer’s protocol to
visualize target proteins (using a Li-Cor Odyssey imaging sys-
tem). Western blot data were quantitatively analyzed using
Odyssey software and values were subsequently normalized
against those of b-actin.
Detection of phospho-S2448 mTOR in cell lysates by ELISA
Phosphorylation of mTOR was analyzed by ELISA as described
before.23 Brieﬂy, 96-well ELISA plates were coated with mouse
anti-mTOR antibodies followed by blocking with 2% BSA. Cell
lysates were then added to the wells and incubated at room
temperature for 2 h (with constant agitation). Plates were then
washed with Tris-Buffered Saline containing Tween 20 (TBST).
Following washing with TBST buffer plates were incubated
with HRP-labeled goat anti-rabbit IgG for 1 h at room temper-
ature. Plates were then washed using TBST and bound second-
ary antibodies were visualized by the peroxidase reaction
(ortho-phenylenediamine/H2O2).
In-cell Western and in-cell (on-cell) assay
We employed a standard Li-Cor in-cell Western assay to ana-
lyze total Tim-3 and galectin-9 expressions in the studied cells.4
The in-cell (also called on-cell) assay was employed to
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characterized Tim-3 and galectin-9 surface presence in the
studied cells.
Characterization of Tim-3 and galectin-9 interactions in
cell lysates
An ELISA-based analysis was used where plates were ﬁrst
coated with anti-galectin-9 antibody followed by blocking with
2% BSA. Cell lysates were then applied and incubated for at
least 4 h at room temperature after which plates were exten-
sively washed with TBST. A glycine-HCl pH lowering buffer
(pH 2.0) was then applied to extract the bound proteins.
Extracts were mixed with equal volumes of lysis buffer (pH 7.5)
and with 4£ sample buffer for SDS-PAGE at a ratio of 1:3.
Samples were then subjected to Western blot analysis, using
rabbit anti-galectin-9 and mouse anti-Tim-3 primary antibod-
ies, as described above. The plate was subjected to analysis with
galectin-9 detection antibody followed by standard ELISA steps
to ensure that no galectin-9 remained in the wells. Signals
obtained were similar to those where PBS was used instead of
the sample conﬁrming that all the protein was extracted.
Detection of galectin-9 and VEGF secretion, soluble forms
of Tim-3 and Tim-3-galectin-9 complexes
Galectin-9 and VEGF levels released into the medium were
analyzed by ELISA (R&D Systems assay kits) according to the
manufacturer’s instructions. Soluble Tim-3 was detected using
similar approach where mouse anti-Tim-3 (mAnti-Tim-3) was
employed as a capture antibody and rabbit anti-Tim-3 (rAnti-
Tim-3)—for detection (Fig. 6C, scheme). HRP-labeled anti-
Rabbit secondary antibody (Abcam) was used to visualize the
reaction. Tim-3-galectin-9 complexes in blood plasma were
detected by ELISA. Mouse anti-Tim-3 (mAnti-Tim-3) was
employed as a capture antibody and biotinylated goat anti-
galectin-9 (gAnti-Galectin-9, R&D Systems) as detection anti-
body. The reaction was visualized using HRP-labeled streptavi-
din (R&D Systems; Fig. 6C, scheme). In all cases plates were
washed using TBST and bound secondary antibodies visualized
by the peroxidase reaction (ortho-phenylenediamine/H2O2).
Characterization of glycolysis and MGO levels
Glycolytic degradation of glucose was analyzed using a colori-
metric assay as described before.20 Brieﬂy, the approach was
based on the ability of cell lysates, used as a multi-enzyme prepa-
ration, to convert glucose into lactate in the absence of oxygen
(this was achieved by employing an anaerobic chamber). Cell
lysates were incubated for 1 h at 37C with 1% glucose solution
within the anaerobic chamber. 2% trichloroacetic acid solution
was then used to precipitate proteins. This was followed by
carbohydrate precipitation using saturated CuSO4 solution in
combination with Ca(OH)2 (at a ﬁnal concentration of
60 mg/mL). Lactate was then converted into acetic aldehyde
using concentrated H2SO4 at 90C for 1 min and cooled the sam-
ples down on ice. We then detected acetaldehyde using the vera-
trole (1,2-dimethoxybenzene) test. MGO was also detected
colorimetrically following biochemical modiﬁcations.24,25 Brieﬂy,
MGO was condensed with reduced glutathione (GSH, 1 mM)
for 10 min at 37C. The complex was then converted into lactate
by Glyoxalases I and II at pH 8.0 (Glyoxalase I converted the
complex in D-lactoyL-glutathione, which was then transformed
into lactate by Glyoxalase II26). The whole process is highlighted
in Fig. S2). Lactate was then measured colorimetrically as
described above.
Statistical analysis
Each experiment was performed at least three times and sta-
tistical analysis was conducted using a 2-tailed Student’s t
test. Statistical probabilities (p) were expressed as p < 0.05,
p < 0.01, and p < 0.001.
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